SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - FRA:56S1 - FR0013154002 - Common Stock
194.3 EUR
+6.15 (+3.27%)
56S1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. 56S1 has only an average score on both its financial health and profitability. 56S1 shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year 56S1 was profitable.
In the past year 56S1 had a positive cash flow from operations.
Each year in the past 5 years 56S1 has been profitable.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
56S1's Return On Assets of 3.35% is in line compared to the rest of the industry. 56S1 outperforms 47.37% of its industry peers.
Looking at the Return On Equity, with a value of 6.54%, 56S1 is in line with its industry, outperforming 47.37% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.94%, 56S1 is in line with its industry, outperforming 47.37% of the companies in the same industry.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 8.08%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
The Profit Margin of 56S1 (8.96%) is better than 68.42% of its industry peers.
In the last couple of years the Profit Margin of 56S1 has declined.
With a decent Operating Margin value of 16.63%, 56S1 is doing good in the industry, outperforming 63.16% of the companies in the same industry.
In the last couple of years the Operating Margin of 56S1 has declined.
The Gross Margin of 56S1 (45.64%) is better than 68.42% of its industry peers.
In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
Compared to 5 years ago, 56S1 has more shares outstanding
56S1 has a better debt/assets ratio than last year.
2.2 Solvency
56S1 has an Altman-Z score of 4.26. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
56S1's Altman-Z score of 4.26 is amongst the best of the industry. 56S1 outperforms 89.47% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of 56S1 (6.84) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 57.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.26 |
ROIC/WACC0.67
WACC8.83%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1's Current ratio of 1.05 is on the low side compared to the rest of the industry. 56S1 is outperformed by 68.42% of its industry peers.
A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
With a Quick ratio value of 0.50, 56S1 is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.11% over the past year.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
The Revenue has been growing slightly by 7.72% in the past year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
The Earnings Per Share is expected to grow by 22.11% on average over the next years. This is a very strong growth
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.12% yearly.
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 45.08 indicates a quite expensive valuation of 56S1.
73.68% of the companies in the same industry are cheaper than 56S1, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of 56S1 to the average of the S&P500 Index (26.35), we can say 56S1 is valued expensively.
A Price/Forward Earnings ratio of 36.49 indicates a quite expensive valuation of 56S1.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than 73.68% of the companies in the same industry.
56S1 is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 33.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.08 | ||
| Fwd PE | 36.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 56S1 is valued more expensive than 84.21% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 50.5 | ||
| EV/EBITDA | 26.21 |
4.3 Compensation for Growth
56S1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1 has a very decent profitability rating, which may justify a higher PE ratio.
56S1's earnings are expected to grow with 22.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.59
PEG (5Y)10.75
EPS Next 2Y23.34%
EPS Next 3Y22.86%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.36%, which is pretty low.
56S1's Dividend Yield is comparable with the industry average which is at 0.76.
With a Dividend Yield of 0.36, 56S1 pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
FRA:56S1 (11/11/2025, 7:00:00 PM)
194.3
+6.15 (+3.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.91B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target239.05 (23.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.17%
PT rev (3m)-0.64%
EPS NQ rev (1m)9.76%
EPS NQ rev (3m)9.76%
EPS NY rev (1m)0.52%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)5.19%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.08 | ||
| Fwd PE | 36.49 | ||
| P/S | 6.42 | ||
| P/FCF | 50.5 | ||
| P/OCF | 25.88 | ||
| P/B | 4.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.21 |
EPS(TTM)4.31
EY2.22%
EPS(NY)5.32
Fwd EY2.74%
FCF(TTM)3.85
FCFY1.98%
OCF(TTM)7.51
OCFY3.86%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.59
PEG (5Y)10.75
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.26 |
F-Score8
WACC8.83%
ROIC/WACC0.67
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y28.28%
EPS Next 2Y23.34%
EPS Next 3Y22.86%
EPS Next 5Y22.11%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year8.96%
Revenue Next 2Y9.07%
Revenue Next 3Y9.84%
Revenue Next 5Y10.12%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.68%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 6 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.41%.